<SEC-DOCUMENT>0001493152-18-007496.txt : 20180521
<SEC-HEADER>0001493152-18-007496.hdr.sgml : 20180521
<ACCEPTANCE-DATETIME>20180521072335
ACCESSION NUMBER:		0001493152-18-007496
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180521
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180521
DATE AS OF CHANGE:		20180521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		18848386

	BUSINESS ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		175 DERBY ST. 27/1
		STREET 2:		.
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
the Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date
of Report (Date of earliest event reported): May 21, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>MICROBOT
MEDICAL INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-19871</B></FONT></TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94-3078125</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
        or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Commission</B></FONT></P>
                                                                             <P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>File Number)</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(IRS
        Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>25 Recreation Park Drive, Unit 108</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Hingham, Massachusetts 02043</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Address of Principal Executive Offices) (Zip Code)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code: (781) 875-3605</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
&sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
    FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 21, 2018, Microbot Medical Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that it has successfully completed
a pre-clinical study for its Self-Cleaning Shunt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be
&ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including
Exhibit 99.1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
    9.01.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(d)
Exhibits</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 0.75in; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="width: 0.1in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated May 21, 2018</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
May 21, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="Description: C:\Users\MPolyviou\AppData\Local\Microsoft\Windows\INetCacheContent.Word\microbot.jpg" STYLE="height: 87px; width: 225px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Successfully Completes Pre-Clinical Study for its Self-Cleaning Shunt</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Data
from Pre-Clinical Study Indicates the Self-Cleaning Shunt has the Potential to be a Viable Technology for Preventing Occlusion
in Shunts Used to Treat Hydrocephalus</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hingham,
MA&ndash; May 21, 2018 &ndash; Microbot Medical Inc. (NASDAQ CM: MBOT), a medical device company specializing in the design and
development of transformational micro-robotic medical technologies, today provided the results of a pre-clinical study assessing
the Company&rsquo;s Self-Cleaning Shunt (SCS). The in-vitro study, which was performed at Wayne State University by Dr. Carolyn
Harris, supports the SCS&rsquo;s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Initial
results from the first phase of the study, conducted in an in-vitro 3D cell culture system built to mimic the ventricular environment,
showed that cells attach, grow and spread across the shunt drainage holes of the Microbot SCS,&rdquo; said Dr. Harris, Assistant
Professor of Chemical Engineering and Materials Science, Wayne State University. &ldquo;Although further research is necessary,
the small-scale study shows that the Microbot SCS can potentially remove this early spreading of cells across the shunt holes,
which is a first step towards the main target of the study - occlusion prevention.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
study results are highly encouraging and affirm our confidence in the SCS&rsquo; technology as a novel solution to prevent occlusion
in hydrocephalus shunts, as well as a potential platform for future occlusion prevention devices for other medical applications,&rdquo;
commented Harel Gadot, Chief Executive Officer, President and Chairman. &ldquo;We have already been executing the next development
phase of our SCS, and together with our recent facility upgrade to support these activities, we believe we are on the right track
to deliver the first occlusion prevention device for the countless patients suffering with hydrocephalus while eliminating unnecessary
procedures and reducing the cost of healthcare.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will proceed with the larger-scale studies to support the SCS and prepare it for regulatory submissions in the USA, Europe
as well as other regions across the globe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot,
which was founded in 2010 and commenced operations in 2011, became a NASDAQ listed company on November 28, 2016. The Company specializes
in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot&rsquo;s
current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is
currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and
Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for
use in colonoscopy procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body. Its miniature
dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract
and the respiratory system. Its unique structure gives it the ability to move in tight spaces and curved passages as well as the
ability to remain within the human body for prolonged time. To learn more about ViRob please visit http://www.microbotmedical.com/technology/virob/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TipCAT
is a transformational self-propelled, flexible, and semi-disposable endoscope providing see &amp; treat capabilities within tubular
lumens in the human body such as the colon, blood vessels, and the urinary tract. Its locomotion mechanism is perfectly suitable
to navigate and crawl through natural &amp; artificial tubular lumens, applying the minimal necessary pressure to achieve the
adequate friction required for gentle, fast, and safe advancement within the human body. To learn more about TipCAT, visit http://www.microbotmedical.com/technology/tipcat/.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical
fact (including, but not limited to statements that contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;expects&rdquo; and &ldquo;estimates&rdquo;) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development
and/or commercialization of potential products, the outcome of its studies to evaluate the SCS and other existing and future technologies,
uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many uncertainties that affect the businesses of Microbot Medical
Inc. particularly those mentioned in the cautionary statements found in Microbot Medical Inc.&rsquo;s filings with the Securities
and Exchange Commission. Microbot Medical disclaims any intent or obligation to update these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contacts: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analysts
and Institutional Investors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-232-6914</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
Investors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy
Roe</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integra
Consulting Group llc</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jeremy@integracg.net</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(925)
262-8305</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5P#A P$1  (1 0,1 ?_$ +T  0 # 0$  P$!
M       '" D*!@$"!00# 0$  @(# 0$              0(#! 8'" D%$
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M'V^86+.6\2CI_J[3R7C&#,R,IYR!B=;<:4,M2N2OXMV$[K4=Q"^?Q7EDA_\
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M%I5;@O?.?AN?T\GUXO*3"<: @-]IR#Y6[0,:D [.9N''ZA8V8((ANJ<Y9=H
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M[@%XV$.9E-E\UY9R'<JQC\T](URBUBFO/IK^4:02QV3F8F94Q5')R*NB&!%
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MYIW';+_:;V7;=SAEM]Q@>6R1R-+'L<,PYKJ$?\,0L/8FPW7%MFCK=7'3NKY
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M:BRJ6]$51^>7\'O(']W[[^MLM9(OQ!\U5WI7'15O^*&*-P 0'-&.=P'X#_\
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M_+WC5CB=+6[OF2E5Z7,J")FSR1$Q$3B<$]G#E!-5N@!3F #&,8"D_2$.NNW
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J"]ICI8'_ *CL6GYG3J3A86[GU!7],' %-OW@7X#JOS4X?56 T1-$7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
